(RTTNews) - Genprex Inc. (GNPX) reported positive preliminary preclinical results for its diabetes gene-therapy candidate GPX-002, showing in-vivo proof-of-concept in both Type 2 diabetic non-human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback